Long-term Remission Over Six Years for a Patient with Recurrent Glioblastoma Treated with Cediranib/Lomustine

Cediranib is an orally available, pan-VEGFR tyrosine kinase inhibitor. A previous Phase III study of patients with recurrent glioblastoma treated with this drug did not meet the primary end of progressive-free survival (PFS). We identified one patient, a 57-year-old Caucasian female who, following s...

Descripción completa

Detalles Bibliográficos
Autores principales: Drazin, Doniel, Al-Khouja, Lutfi, Patel, Ashish, Hu, Jethro, Phuphanich, Surasak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2016
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4757029/
https://www.ncbi.nlm.nih.gov/pubmed/26929887
http://dx.doi.org/10.7759/cureus.460

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4757029/
https://www.ncbi.nlm.nih.gov/pubmed/26929887
http://dx.doi.org/10.7759/cureus.460

Ejemplares similares